Press Releases Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Market Closed - Euronext Amsterdam Other stock markets 11:35:08 2024-05-16 am EDT			5-day change	1st Jan Change
0.752 ^EUR	-1.44%		-9.40%	-90.76%

Apr. 24	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Mar. 15	Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024	May. 15	GL
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024	May. 08	PU
Vivoryon Therapeutics N : to Hold its 2024 Annual General Meetingon June 21, 2024	May. 08	PU
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024	May. 08	GL
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	Apr. 24	PU
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	Apr. 24	GL
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	Apr. 24	AQ
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024	Apr. 16	GL
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Announces Changes to Board Composition	Mar. 15	PU
Vivoryon Therapeutics N.V. Announces Changes to Board Composition	Mar. 15	GL
Vivoryon Therapeutics N.V. Announces Changes to Board Composition	Mar. 15	AQ
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	Mar. 04	PU
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	Mar. 04	GL
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	Mar. 04	AQ
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	Jan. 08	GL
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	Jan. 08	AQ
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	Dec. 06	GL
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	Dec. 06	AQ
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023	Nov. 28	GL
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference	Nov. 07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Press Releases

Filters